# Efficacy and Safety of DHEA for Myotonic Dystrophy

> **NCT00167609** · PHASE2,PHASE3 · COMPLETED · sponsor: **University of Versailles** · enrollment: 75 (actual)

## Conditions studied

- Myotonic Dystrophy

## Interventions

- **DRUG:** dehydroepiandrosterone 100 and 400 mg

## Key facts

- **NCT ID:** NCT00167609
- **Lead sponsor:** University of Versailles
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** —
- **Final completion:** 2006-12
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2010-04-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00167609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00167609, "Efficacy and Safety of DHEA for Myotonic Dystrophy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00167609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*